IPATential150 is a phase III, randomised, double-blind study evaluating the efficacy and safety of adding ipat to abi in asymptomatic or mildly symptomatic pts previously untreated for mCRPC. Preclinically, dual pathway inhibition has greater antitumor activity than AR inhibition. PTEN loss (40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse outcomes.
![ipartition trial version ipartition trial version](https://www.insanelymac.com/blog/wp-content/uploads/2021/01/partitioning-disk-utility.png)
PI3K/AKT and androgen receptor (AR) signalling are dysregulated in mCRPC.
![ipartition trial version ipartition trial version](https://mac-cdn.softpedia.com/screenshots/iPartition_9.jpg)
#IPARTITION TRIAL VERSION SKIN#
![ipartition trial version ipartition trial version](http://www.macyourself.com/wp-content/uploads/2011/03/031611-ipartition-screen1.jpg)
#IPARTITION TRIAL VERSION SERIES#
ESMO Webinar Series on-demand recordings.Clinical Pharmacology of Anti-Cancer Agents.Cancer Treatment in Special Clinical Situations.Rehabilitation Issues During Cancer Treatment and Follow-Up.Cancer Diagnosis and Treatment Evaluation.Interpreting Oncological Study Publications.